Development and therapeutic evaluation of 5D3(CC-MLN8237)3.2 antibody-theranostic conjugates for PSMA-positive prostate cancer therapy

• Main Authors: Ioanna Liatsou (Author), Betelhem Assefa (Author), Wathsala Liyanage (Author), Sharmane Surasinghe (Author), Zora Nováková (Author), Cyril Bařinka (Author), Kathleen Gabrielson (Author), Venu Raman (Author), Dmitri Artemov (Author), Sudath Hapuarachchige (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Prostate cancer (PC) is an aggressive cancer that can progress rapidly and eventually become castrate-resistant prostate cancer (CRPC). Stage IV metastatic castrate-resistant prostate cancer (mCRPC) is an incurable late-stage cancer type with a low 5-year overall survival rate. Targeted therapeutics...